StemCell Therapy

SPRINGFIELD Illinois sex offender registry, which now includes more than 32,000 people most of them men, though some women, as well has rapidly expanded since its first iteration in 1986.

Then, it included four qualifying crimes. Today, there are more than 30 crimes that trigger mandatory registration, including some repeat misdemeanor offenses.

In recent years, policy makers and advocates, both for offenders as well as victims, have been raising questions as to whether the registry, and the ever-increasing rules around it, really makes the public safer, or causes more societal harm than it does good.

In 2018, a bipartisan task force recommended Illinois take a far more nuanced approach to its registry, providing for risk assessments that allow law enforcement to focus limited resources on monitoring and more robust treatment options for people who are at high risk of re-offending.

The task force also recommended that those who pose less risk automatically fall off the registry after a set period of time. In fact, one of the key findings of the group is that the registry has not lived up to its mission.

While public opinion surveys show that the public favors a freely available sex offender registry research has not established that registries have any effect on the sexual crime rate, the task force wrote in its final report.

The General Assembly has not taken any significant action on the recommendations in the two years since.

In the coming months, The Lee Enterprises Midwest reporting team, which includes The Southern Illinoisan, will examine the government systems established to protect children from abuse, specifically sexual abuse, including complex registry laws and residency restrictions.

Registry rules run amok?

About one out of every 200 adult men who live in Illinois is required to register.

There are hundreds of people on the registry across Southern Illinois.

Some registrants are homeless. Others languish in Illinois prisons long after their eligible parole date because they cant find a place to live that meets stringent residency restrictions.

Most people with a sex offense conviction on their record are prohibited from living within 500 feet of a school, day care, park or other child-based facilities.

Rural areas of the state, including many Southern Illinois counties, are home to a disproportionate share of people on the registry, though a large percentage of the people who live here were convicted in other counties, an analysis of the registry shows.

That may be, in part, because residency restrictions severely limit housing options in non-rural areas.

People with a sex offense conviction on their records must register either for 10 years or a lifetime. Most people on the list have been labeled sexual predators and must register annually for their natural life.

With the exception of some juvenile cases, and other than death, there is no mechanism by which the majority of registrants can have their names removed.

On the whole, criminal justice policy has moved in the opposite direction: toward shorter sentences, an attempt to mitigate factors that contribute to crime, and a heavier emphasis on treatment and rehabilitation. Meanwhile, Illinois registry has grown by more than 20% in the past decade.

Theres really a national conversation, and its happening in Illinois as well, thats really about rethinking the fundamental nature of criminal justice systems, and what we want them to be and to do, said Ed Yohnka, spokesman for the American Civil Liberties Union of Illinois. But when it comes to people with sex offense convictions, this is an area where we havent been able to move the needle.

Local law enforcement agencies dedicate countless hours to upkeep of the database, including making sure people on the registry live where they say they do. But treatment providers, especially in rural areas, are far and few between. Only a small percentage of people serving time for sex-related convictions receive specialized treatment while in prison.

More importantly, advocates for reform say, the state has done little to remove barriers that allow people with sex convictions to reenter society as they leave prison, even while taking great strides to do so for people who have committed other categories of offenses.

Housing stability is one of the biggest barriers to a successful reentry, as well as longer-term success for people who have served time for any offense. People with past sex offenses often face the greatest challenges to securing stable housing, said Laurie Jo Reynolds, an organizer with the Chicago 400 Alliance, an alliance of victim, criminal justice and housing advocates working to address homelessness and housing instability resulting from state residency restrictions.

The extensive restrictions on where people can live effectively banish people from legally living within many cities and towns, Reynolds said. Further, there are no transitional housing facilities for people with sex convictions licensed by the Illinois Department of Corrections.

People with a past sex conviction are not allowed to rent government-subsidized housing. A person on parole for a sex-related crime cannot rent a place at an apartment complex that houses any other individual on the registry.

"Housing is the foundation for a stable, productive life, but Illinois laws force people into homeless even when they have homes," Reynolds said. "It also causes 1,400 people to be detained in prison after their release dates. Its difficult to re-enter society if you cant leave prison and if we banish you from all housing."

Further, it does nothing to advance public safety, and may have the opposite effect, she added.

Criminal justice research has consistently held that stable housing, work and social standing are among the most important factors to reducing crime all of which registry and residency laws make challenging to attain.

People with past sex offense convictions face high rates of homelessness.

In Chicago, one in five people on the registry are homeless. That means they have to report their whereabouts to law enforcement on a weekly, rather than annual, basis. Of those who are homeless in Chicago, 80% are Black men who live on the citys west and south sides, according to the Chicago 400 Alliance. In Illinois, a Black man is more than three times as likely to have to register than a white man.

Origins of a complex law

When Terry Parke, a state representative from Pittsfield, the chief sponsor of the Habitual Child Sex Offender Registration Act, discussed his 1986 bill, the origins of Illinois registry, he described it as one of the most important laws the legislature would consider that year.

We are having an epidemic in Illinois of sex crimes against our children. Parke said in pleading his case for the bill.

Another lawmaker, Rep. Robert Regan, a Republican from the south suburbs of Chicago, implored his colleagues to remember that pedophiles are compulsive and repetitive.

The law required habitual child sex offenders to register with police within 30 days of their release from prison and remain registered for 10 years.

This first registry was only for law enforcement use, and included people who were released from state custody and had been convicted of criminal sexual assault, aggravated criminal sexual assault, criminal sexual abuse or aggravated criminal sexual abuse.

In the decade that followed, numerous states passed similar laws. Many of them were prompted by Congress 1994 passage of the Jacob Wetterling Crimes Against Children and Sexually Violent Offender Registration Act. The law was named for an 11-year-old boy from Minnesota kidnapped in 1989 by a stranger. It required states to establish registration systems for law enforcement to quickly identify people convicted of offenses against children and sex-related crimes.

The goal was to help law enforcement with investigations before technological advances made it possible for them to easily and quickly view previous convictions to vet suspects.

Two years later, Congress moved to make state registries available to the public with the passage of Megans Law. The legislation was inspired by a 7-year-old girl from New Jersey who was raped and murdered by a man who had previously been convicted of sexually assaulting two other young girls.

When state registries first came into being, there was a sense on the part of many that the intended target was the worst of the worst repeat offenders who repeatedly preyed on children, said Yohnka, of the ACLU.

Instead, its burgeoned into this thing that no longer reflects that, he said. Im not certain it is in any way fulfilling the goal, the original intent of the list themselves.

Abusers most often known to victims

Decades of secrecy, especially around child sexual abuse, limiting disclosure and prosecution, coupled with tough-on-crime political rhetoric, has fueled numerous public misconceptions on this issue.

For instance, though the term was referenced during the 1986 debate for the state's initial registry, most people on the registry today do not have pedophilic disorder, which is a psychosexual disorder characterized by sexual attraction to prepubescent children, according to experts.

In 2010, during floor debate in the Illinois House concerning a bill to restrict people with past sex convictions from parks and forest preserves, then-Rep. Dennis Reboletti, a Republican from Elmhurst, argued that these people recidivate at 40 or 50 or 60 percent of the time.

Indeed, a May 2019 Department of Justice study found that half of released sex offenders had a subsequent arrest that led to a conviction. However, the study found these convictions were far more likely to be for a non-sex-related offense, such as a property crime, drug offense or parole violation. Further, the recidivism rate of people with sex offense convictions over a nine-year period, from 2005 to 2014, was lower than that of people with other types of convictions.

Your membership makes our reporting possible.

A 2015 report from the Justice Department found that the rate at which people with past sex convictions commit a repeat sex offense range from 1% to 22%, depending on their risk level.

Although sex offenders are often viewed as a homogenous group by the public, the report noted, in reality they have committed an array of illegal acts, ranging from noncontact offenses such as exhibitionism to violent sexual assaults.

According to the Justice Department report, the recidivism rate for high-risk offenders is 22% from the time of release. For those who have lived 10 years in the community offense free, the rate decreases to 4.2%. The recidivism rates of low-risk offenders are consistently low, at 1% to 5%, the study found.

Among the thousands of people on Illinois registry, the details of their cases and crimes vary greatly, even though most in Illinois share the label sexual predator. No risk assessment information is included.

A complicating factor in determining recidivism rates is that most incidences of sexual abuse are not reported. Children, especially, are known to wait years to disclose what happened to them.

Thats because they are far more likely to be abused by someone they know, and oftentimes love and trust, than by a person unknown to them regardless of whether they are on a registry.

According to RAINN (Rape, Abuse & Incest National Network), the largest anti-sexual violence organization in the U.S., children and teens who are sexually abused know the perpetrator in more than 90% of cases. In just over a third of cases, perpetrators are family members; they are acquaintances to the child or family in about 60% of cases.

Child victim advocates support changes

Even some of the most strident defenders of child victims say it is time for a reexamination of the registry.

Dr. Kathy Swafford speaks at a Child Abuse Prevention event.

Dr. Kathy Swafford, executive director of the Childrens Medical and Mental Health Resource Network, a division of the Southern Illinois University School of Medicine, works with child sex abuse victims across downstate Illinois. She said a registry does serve a purpose for victims, families and advocates, but believes it should be more targeted and specific.

Swafford said a risk-assessment component that distinguishes those who are repeat offenders or otherwise deemed high risk from low-risk offenders is an approach that makes sense.

If youre on the lower level, the lower tier whatever we decide those crimes might be then as far as affecting your employment or being held against you forever, I dont know that thats correct, she said.

Victor Vieth, with the Zero Abuse Project, an organization that aims to end sexual abuse against children, said the issue of registries is a complex topic that deserves additional debate and more study. He opposes any efforts to quickly relax standards during the pandemic, saying children, many of whom are out of school, are at increased risk right now. But, Vieth said there is room to improve registries to make them more effective.

Once we come out on the other side of the pandemic we can revisit the border issues of registration, he said. Probably some people need to be on the registry for life, and we need to monitor them closely. There are probably others who are not as much of a danger who we could relax the standards on.

Some Illinois prosecutors and law enforcement officers have a different take on it.

Having tried cases involving horrific crimes against children, Williamson County States Attorney Brandon Zanotti said he doesnt think lifetime registry is too long for those crimes that mandate it. As a caveat, he added that the law already includes the ability for people whose mandated life registration stems from a crime they committed as a juvenile to petition the court for review of their status.

Zanotti said some investigations start because a member of the public reports suspicious or illegal behavior by a registrant. For instance, Zanotti said his office received a complaint a few weeks ago that a person on the registry had signed up to serve as an election judge, which the law doesnt allow. The individual was notified he could not serve prior to election day and a replacement was found.

New laws added annually

During floor debate in 1986, some lawmakers pushed back on creation of what, in hindsight, was a relatively conservative approach to a state registry intended to aid law enforcement in investigations.

Then-Rep. Larry Hicks, a Mount Vernon Democrat, said it was inappropriate to tell those who served their time for a conviction that were going to then register them and try to brand them for years to come.

But the bill easily earned the approval of the chamber and then sailed through the Senate without dissent, according to a legal examination of the registry in a 2010 article published by the Northwestern Journal of Law & Social Policy.

While the atmosphere under the dome in Springfield is often divisive and partisan, Republican and Democratic lawmakers have largely stood united in support of increasingly harsh punishments for people who commit sex crimes. By the same token, theyve shied away from taking up any significant reforms to the registry.

Since the laws passage, lawmakers have passed in excess of 100 new rules and restrictions targeting people with past sex convictions.

In fact, each year seems to usher in a host of new laws sometimes one by one.

Seven years after passage of the initial law, lawmakers extended the registration requirement to those whose victims on a first offense were under 18. In 1996, they took it a step further, requiring everyone convicted of a sex offense, regardless of victim age, to register. It applied retroactively to anyone convicted of a sex offense in the previous decade.

That same year, the General Assembly moved to make the registrys names, addresses and offenses available to the public, rather than only law enforcement the easily searchable Illinois State Police Sex Offender website launched three years later.

In 1998, passage of a new law prohibited those with sex offense convictions from loitering within 1,000 feet of a school or playground. And in 2000, lawmakers passed a law prohibiting those with child sex convictions from living or being within 500 feet of schools, playgrounds, child care institutions, daycares and other facilities that primarily serve children.

Though many states have since passed residency restrictions, it was one of the most restrictive laws of its kind at the time.

Only three other states preceded Illinois in adopting similar rules.

Additional registry-related rules and restrictions followed passage of the federal 2006 Adam Walsh Child Protection and Child Safety Act, championed by a father whose 6-year-old son was kidnapped and murdered in 1981. The most significant portion of the law sought to establish uniform and comprehensive sex offender registration and notification requirements across the states.

For instance, it sought to increase the amount of information collected on registries and expand crimes that require registration. As well, it sought to make states require registration of juveniles who are at least 14 years old when adjudicated delinquent for certain sexual offenses, and make registries retroactive by requiring all people convicted of sex offenses to register regardless of date of conviction.

Tough-on-crime politics

While many different events prompted the layers of legislation, people who work inside the Capitol building and track criminal justice legislation observe that even-numbered election years seem to bring about the most changes to the registry and restrictions.

Because there is little, if any, organized opposition to these and other sex offender bills, there has been little political debate about the long-term effects of Illinois regulatory scheme, read the 2010 Northwestern Journal of Law report, Putting the Brakes on the Preventative State: Challenging Residency Restrictions on Child Sex Offenders in Illinois under the Ex Post Facto Clause.

Michelle Olson was a young Northwestern law school student when she wrote the article. Ten years later, she works for a private law firm in Chicago, and hasnt kept up with the policy discussions on the topic. She stressed that shes not an expert on the current best practices regarding registries.

But she remembers her motivation to write about it at the time.

Prior to beginning law school in 2007, she spent four years working for both the Illinois House Democrats, a government job, and the Illinois Democratic Party.

During campaign season, she would go on leave from her government work and party leaders would assign her to work the campaigns of lawmakers facing tough reelections. Year after year in her government job, she witnessed lawmakers introducing new legislation concerning people who commit sex offenses, and pass the bills with little substantive debate. Later, those votes would turn up in campaign material.

You probably see if you look back then, and even now, there are a lot of mail pieces from both parties about being tough on crime and cracking down on sex offenders, she said. It was sort of a standard talking point for a long time. But I came out of that process just wondering, is this really effective? Is this really solving the problem? Are we actually damaging some peoples lives beyond repair for a talking point?

Lawmakers have long hesitated to vote or speak against any legislation that could be perceived as going easy on those who commit crimes against children. During debate, they preface questions by first stating their disapproval of those who commit sex crimes.

"None of us ... would do anything that's going to even give the appearance of coddling a sex offender," former Rep. Ken Dunkin, a Chicago Democrat, said before asking why lawmakers were not advocating a more comprehensive approach to managing people with sex offense convictions.

He was speaking during the 2010 floor debate about disallowing people with past sex offense convictions in parks or forest preserves, whether or not children are present.

Former Rep. John Fritchey, also a Chicago Democrat, took it a step further and admonished his colleagues for bringing up this and similar bills, one after another. So many of these people are going to vote for this bill for political cover and to avoid a hit, and to avoid a mail piece, not because it affects a policy , he said.

Kevin Barlow of The (Bloomington) Pantagraph contributed.

molly.parker@thesouthern.com

618-351-5079

On Twitter: @MollyParkerSI

Get the latest in local public safety news with this weekly email.

Read the original post:
Hundreds of Southern Illinoisans are required to register as sex offenders. But are we any safer? - The Southern

Bamlanivimab is a SARS-CoV-2-neutralizing antibody that emerged from the collaboration between Lilly and Vancouver-based AbCellera

TORONTO, Nov. 24, 2020 /CNW/ -Eli Lilly Canada announced today that Lilly and the Government of Canada have signed an agreement for the supply of bamlanivimab to Canada. Lilly will supply Canada with an initial quantity of 26,000 doses of bamlanivimab over the three-month period between December 2020 and February 2021, for US$32.5 million. Lilly is taking a data-driven approach to the worldwide allocation of bamlanivimab according to our guiding principlesthat prioritize countries according to their medical need. Additional doses will be supplied to Canada on a monthly basis according to the medical need in Canada and the availability of supply.

The Government of Canada will be working with provincial and territorial partners to equitably allocate supply, while recognizing the need for flexibility based on COVID-19 activity across the country.

Bamlanivimab received authorization for its use as a treatment of adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who weigh at least 40 kg and are at high risk of progressing to severe COVID-19 illness and/or hospitalization on November 20, 2020 under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.

"From the beginning of our collaboration with AbCellera in March, through the interim authorization for the use of bamlanivimab in November, to an agreement on supply just days later, Lilly is bringing the full force of our expertise to meeting the challenge of COVID-19 in Canada, and around the world," said Rhonda Pacheco, President and General Manager, Lilly Canada. "We're grateful to the Government of Canada for their collaboration in working to quickly make this medicine available for Canadians."

About bamlanivimabBamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Lilly has successfully completed a Phase 1 study of bamlanivimabin hospitalized patients with COVID-19 (NCT04411628).A Phase 2 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

About BLAZE-1BLAZE-1 (NCT04427501) is arandomized, double-blind, placebo-controlled Phase 2 study designed to assess the efficacy and safety of bamlanivimab alone or in combination with a second antibody for the treatment of symptomatic COVID-19 in the outpatient setting. To be eligible, patients were required to have mild or moderate symptoms of COVID-19 as well as a positive SARS-CoV-2 test based on a sample collected no more than three days prior to drug infusion.

The monotherapy arms of the trial enrolled mild to moderate recently diagnosed COVID-19 patients, studying three doses of bamlanivimab (700 mg, 2800 mg, and 7000 mg) versus placebo. The primary outcome measure for the completed arms of the BLAZE-1 trial was change from baseline to day 11 in SARS-CoV-2 viral load. Additional endpoints include the percentage of participants who experience COVID-related hospitalization, ER visit or death from baseline through day 29, as well as safety.

The study is ongoing with additional treatment arms. Across all treatment arms, the trial will enroll over 800 participants.

Data from the monotherapy arms of BLAZE-1 were published in the New England Journal of Medicine.

About Lilly's COVID-19 EffortsLilly is bringing the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Existing Lilly medicines are being studied to understand their potential in treating complications of COVID-19, and the company is collaborating with partner companies to discover novel antibody treatments for COVID-19. Lilly is testing both single antibody therapy as well as combinations of antibodies as potential therapeutics for COVID-19. Click herefor resources related to Lilly's COVID-19 efforts.

About Lilly CanadaEli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people's needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism.

Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at http://www.lilly.ca.

For our perspective on issues in healthcare and innovation, follow us on twitter @LillyPadCA

Lilly Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about bamlanivimab (LY-CoV555) as a potential treatment for patients with or at risk of infection from COVID-19, as well as its supply, and reflects Lilly's current beliefs. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization.Among other things, there can be no guarantee thatfuture study results will be consistent with the results to date, that bamlanivimab will prove to be a safe and effective treatment or preventative for COVID-19, that bamlanivimab will receive regulatory approvals or additional authorizations, or that we can provide an adequate supply of bamlanivimab in all circumstances.For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see Lilly's most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

SOURCE Eli Lilly Canada Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2020/24/c2478.html

See the rest here:
Lilly and the Government of Canada sign an agreement for the supply of bamlanivimab to treat COVID-19 in Canada - Benzinga

In the last hundred years, the name of the game in housing and work has been density.

Since 2007, more people globally live in the worlds urban centers than outside of them. In America specifically, that number goes up to 80%. Higher density urban development has come with some costs, like increases in rent across the board relative to wages. The move to cities may, however, have given us a surprising benefit: making us more resistant to pandemics.

At first, such a statement would seem strange, paradoxical even. The idea of heading for the hills to escape a pandemic has been with us at least as long as Boccaccios Decameron, a 14th century work that has a troupe of ten young nobles hiding out in the Italian countryside to escape the Black Death.

How could living closer together make us more resistant to outbreaks of disease?

Thats precisely what I thought, but as the research bears out, one unlikely key to fighting off diseases like Coronavirus may very well be our greater density of settlement.

Lets compare, for example, the Coronavirus outbreak of 2019-2020 with its most obvious historical parallel: the 1918 Spanish Flu pandemic. The case-mortality rate, that is the rate at which infected people die from the disease, is surprisingly comparable for the two diseases. The Spanish flus was somewhere north of 2.5% (although sources disagree on the actual death toll and, thus, the mortality rate), whereas COVID sits at a respectable 2.2%. Its not exactly an apples-to-apples comparison, but remarkable when you look at the disparities in impact.

Whereas Spanish Flu killed around 675 thousand Americans out of a population of 103.2 million (0.65%), Coronaviruss death toll is 248 thousand (as of the writing of this article) of a population of 331 million (0.0007%). Even if Spanish Flu were a full 1% deadlier than Coronavirus, something would have to account for the dramatic drop in mortality.

Now, some obvious explanations would be hygiene practices, knowledge of disease and access to medicine and treatment. Of these, only the third actually makes any real sense. Allow me to explain.

The Spanish Flu pandemic was over a century ago, yes, but hand-washing had been an understood method of preventing communicable disease spread since the 1850s. Even today, with our myriad of disinfecting sanitizers, the Centers for Disease Control (CDC) still recommends washing ones hands thoroughly with soap and water above any other preventative hygiene measure. True, they didnt bathe as much, but having itchy skin and oily hair wont give someone the flu.

I would argue the average person in 1918 knew about as much as the average person in 2020 does about disease. They knew it was spread by sick people, through fluids and breath droplets, and that they should wear masks and keep their distance from people. Masking and social distancing are nothing new, they were tried and true measures imposed during the 1918 pandemic. True, the average American in 1918 wouldnt really have had a firm grasp of the germ theory of disease, but its worth pointing out that you dont really need that information to keep yourself healthy. There might have been other unhygienic practices that were making them sick in other ways, but as for communicable diseases, they understood what they needed to.

No, the only real explanation lies in access to medicine and treatment. First off, there is the quality of therapeutic medicine. In 1918, doctors and nurses had few options for treating influenza patients. Once someone had contracted the disease, they merely had to treat the symptoms and wait for it to pass. Cold compresses to the head, aspirin, water, food and oxygen administered through a mask were the extent of what most patients would have gotten while ill. Add to this the fact that many patients were cared for at home, thus not only spreading the disease throughout the household but also unable to receive professional medical care.

This is where we return to COVID-19. Not only do we now have better treatments available, but we also have better access to those treatments. How exactly? More people now live closer to a hospital or clinic with high quality care.

According to a June, 2020 study from Johns Hopkins, the density of an area had no statistically significant effect on Coronavirus infection rates (in other words, your likelihood of infection didnt vary by population density of your county) and that mortality rates in highly dense counties were lower, sometimes by as much as 11.3%. The researchers theorized this had to do with greater access to medical care and a higher quality of that care.

Now, that doesnt get American cities off the hook just yet. The researchers also found, higher coronavirus infection and COVID-19 mortality rates in counties are more related to the larger context of metropolitan size in which counties are located. Large metropolitan areas with a higher number of counties tightly linked together through economic, social and commuting relationships are the most vulnerable to the pandemic outbreaks.

In other words, its not the density and high population of urban areas that makes them vulnerable, but the high degree of traffic between urban areas and their suburbs and exurbs. If anything, the results advocate against low density suburban housing, from a purely disease-prevention standpoint.

I personally am not a fan of city-living, but I must admit that if housing was more dense and relied less on commuting, America would likely be more resistant to disease outbreaks.

In a strange twist, running off into the countryside like Boccaccios young storytellers might not make you any safer from the plague.

Photo Credit / Star Tribune

Continued here:
Lessons from the pandemic: density may be the best policy - The Pacer

Databridgemarketresearch.com Present Global Stem Cell Banking Market Industry Trends and Forecast to 2027 new report to its research database. The report spread No of pages: 350 No of Figures: 60 No of Tables: 220 in it. This Global Stem Cell Banking Market report takes into consideration diverse segments of the market analysis that todays business ask for. The Global Stem Cell Banking Market report provides estimations of CAGR values, market drivers and market restraints about the industry which are helpful for the businesses in deciding upon numerous strategies. The base year for calculation in the report is taken as 2017 whereas the historic year is 2016 which will tell you how the Global Stem Cell Banking Market is going to perform in the forecast years by informing you what the market definition, classifications, applications, and engagements are. The report helps you to be there on the right track by making you focus on the data and realities of the industry.

The research studies of this Global Stem Cell Banking Market report helps to evaluate several important parameters that can be mentioned as investment in a rising market, success of a new product, and expansion of market share. Market estimations along with the statistical nuances included in this market report give an insightful view of the market. The market analysis serves present as well as future aspects of the market primarily depending upon factors on which the companies contribute in the market growth, crucial trends and segmentation analysis. This Global Stem Cell Banking Market research report also gives widespread study about different market segments and regions.

Global stem cell banking market is set to witness a substantial CAGR of 11.03% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. The increased market growth can be identified by the increasing procedures of hematopoietic stem cell transplantation (HSCT), emerging technologies for stem cell processing, storage and preservation. Increasing birth rates, awareness of stem cell therapies and higher treatment done viva stem cell technology.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-banking-market&pm

Competitive Analysis:

Global stem cell banking market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of inflammatory disease drug delivery market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors:

Few of the major competitors currently working in global inflammatory disease drug delivery market are: NSPERITE N.V, Caladrius, ViaCord, CBR Systems, Inc, SMART CELLS PLUS, LifeCell International, Global Cord Blood Corporation, Cryo-Cell International, Inc., StemCyte India Therapeutics Pvt. Ltd, Cordvida, ViaCord, Cryoviva India, Vita34 AG, CryoHoldco, PromoCell GmbH, Celgene Corporation, BIOTIME, Inc., BrainStorm Cell Therapeutics and others

Market Definition:Global Stem Cell Banking Market

Stem cells are cells which have self-renewing abilities and segregation into numerous cell lineages. Stem cells are found in all human beings from an early stage to the end stage. The stem cell banking process includes the storage of stem cells from different sources and they are being used for research and clinical purposes. The goal of stem cell banking is that if any persons tissue is badly damaged the stem cell therapy is the cure for that. Skin transplants, brain cell transplantations are some of the treatments which are cured by stem cell technique.

Cord Stem Cell Banking MarketDevelopment and Acquisitions in 2019

In September 2019, a notable acquisition was witnessed between CBR and Natera. This merger will develop the new chances of growth in the cord stem blood banking by empowering the Nateras Evercord branch for storing and preserving cord blood. The advancement will focus upon research and development of the therapeutic outcomes, biogenetics experiment, and their commercialization among the global pharma and health sector.

Cord Stem Cell Banking MarketScope

Cord Stem Cell Banking Marketis segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of the cord stem cell banking marketis further analyzed based on maximum granularity into further segmentation. On the basis of storage type, the market is segmented into private banking, public banking. On the basis of product type, the market is bifurcated into cord blood, cord blood & cord tissue. On the basis of services type, the market is segmented into collection & transportation, processing, analysis, storage. On the basis of source, market is bifurcated into umbilical cord blood, bone marrow, peripheral blood stem, menstrual blood. On the basis of indication, the market is fragmented into cerebral palsy, thalassemia, leukemia, diabetes, autism.

Cord stem cell trading is nothing but the banking of the vinculum plasma cell enclosed in the placenta and umbilical muscle of an infant. This ligament plasma comprises the stem blocks which can be employed in the forthcoming time to tackle illnesses such as autoimmune diseases, leukemia, inherited metabolic disorders, and thalassemia and many others.

Market Drivers

Increasing rate of diseases such as cancers, skin diseases and othersPublic awareness associated to the therapeutic prospective of stem cellsGrowing number of hematopoietic stem cell transplantations (HSCTs)Increasing birth rate worldwide

Market Restraint

High operating cost for the therapy is one reason which hinders the marketIntense competition among the stem cell companiesSometimes the changes are made from government such as legal regulations

Key Pointers Covered in the Cord Stem CellBanking MarketIndustry Trends and Forecast to 2026

Market SizeMarket New Sales VolumesMarket Replacement Sales VolumesMarket Installed BaseMarket By BrandsMarket Procedure VolumesMarket Product Price AnalysisMarket Healthcare OutcomesMarket Cost of Care AnalysisMarket Regulatory Framework and ChangesMarket Prices and Reimbursement AnalysisMarket Shares in Different RegionsRecent Developments for Market CompetitorsMarket Upcoming ApplicationsMarket Innovators Study

Key Developments in the Market:

In August, 2019, Bayer bought BlueRock for USD 600 million to become the leader in stem cell therapies. Bayer is paying USD 600 million for getting full control of cell therapy developer BlueRock Therapeutics, promising new medical area to revive its drug development pipeline and evolving engineered cell therapies in the fields of immunology, cardiology and neurology, using a registered induced pluripotent stem cell (iPSC) platform.In August 2018, LifeCell acquired Fetomed Laboratories, a provider of clinical diagnostics services. The acquisition is for enhancement in mother & baby diagnostic services that strongly complements stem cell banking business. This acquisition was funded by the internal accruals which is aimed to be the Indias largest mother & baby preventive healthcare organization.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-banking-market&pm

Research objectives

To perceive the most influencing pivoting and hindering forces in Cord Stem Cell Banking Market and its footprint in the international market.Learn about the market policies that are being endorsed by ruling respective organizations.To gain a perceptive survey of the market and have an extensive interpretation of the Cord Stem Cell Banking Market and its materialistic landscape.To understand the structure of Cord Stem Cell Banking Market by identifying its various sub segments.Focuses on the key global Cord Stem Cell Banking Market players, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Cord Stem Cell Banking Market submarkets, with respect to key regions (along with their respective key countries).To strategically profile the key players and comprehensively analyze their growth strategiesTo analyze the Cord Stem Cell Banking Market with respect to individual growth trends, future prospects, and their contribution to the total market.

Customization of the Report:

All segmentation provided above in this report is represented at country levelAll products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Read more:
Global Stem Cell Banking Market to Get Expansion admist COVID 19, Scope With Advanced Technologies Top Key Players and Forecast 2020-2027 - The...

New York, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Scaffold Technology Market Research Report by Product, by Application, by End-User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05989770/?utm_source=GNW

The Global Scaffold Technology Market is expected to grow from USD 868.36 Million in 2019 to USD 1,377.33 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.99%.

Market Segmentation & Coverage:This research report categorizes the Scaffold Technology to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the Scaffold Technology Market studied across Freeze Embryo Testing, Hydrogels, Micropatterned Surface Microplates, Nanofiber-based Scaffolds, and Polymeric Scaffolds.

Based on Application, the Scaffold Technology Market studied across Cancer, Drug Development, Stem cell research, and Tissue Engineering and Clinical Application.

Based on End-User, the Scaffold Technology Market studied across Biotechnology and Pharmaceutical Organizations, Hospitals and Diagnostic Centers, and Research Laboratories and Institutes.

Based on Geography, the Scaffold Technology Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Scaffold Technology Market including 3D Biomatrix, 3D Biotek LLC, 4titude, Akron Biotech, Akron Biotech, Avacta Life Sciences Limited, Becton, Dickinson and Company, Corning Incorporated, Matricel GmbH, Medtronic PLC, Merck KGaA, Molecular Matrix, Inc., Molecular Matrix, Inc., Nanofiber Solutions, NuVasive, Inc., Pelobiotech, REPROCELL, Inc., Tecan Trading AG, Thermo Fisher Scientific, Inc., and Vericel Corporation.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Scaffold Technology Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Scaffold Technology Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Scaffold Technology Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Scaffold Technology Market?4. What is the competitive strategic window for opportunities in the Global Scaffold Technology Market?5. What are the technology trends and regulatory frameworks in the Global Scaffold Technology Market?6. What are the modes and strategic moves considered suitable for entering the Global Scaffold Technology Market?Read the full report: https://www.reportlinker.com/p05989770/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More here:
Scaffold Technology Market Research Report by Product, by Application, by End-User - Global Forecast to 2025 - Cumulative Impact of COVID-19 -...

Global Cell Therapy Technologies Market 2020 by Manufacturers, Countries, Type and Application, Forecast to 2026 offers a deep analysis of the historical data and prevalent and future growth prospects. The report provides all the necessary information required by new entrants as well as the existing players to gain deeper insight. The report addresses the challenges the market is facing to offer beneficial advantages to the key players in the market. The report comprehensively analyzes global Cell Therapy Technologies market size, segmentation market growth, market share, sales analysis, strategic market growth analysis, and product launches. The report attempts to build familiarity with the market by representing basic information associated with aspects such as market definitions, classifications, applications, product specifications, manufacturing processes, cost structures, and raw materials. The global Cell Therapy Technologies market report analyzes also features the revenue, industry size, share, production volume.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/30084

Competitive Analysis:

The report centered on vendors available in the market combined with price, quality, brand, product differentiation, and product portfolio. Pricing analysis is provided in the report, which is examined in accordance with different regions and product type segments. In addition, this report introduces a market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report. This market research report on the global Cell Therapy Technologies market analyzes the growth prospects for the key vendors operating in this market space including Danaher, Thermo Fisher Scientific, Merck, Terumo, BD, Lonza Group, GE Healthcare, Sartorius, Stemcell Technologies, Miltenyi Biotec,

What Is The Regional Framework?

Next part of the report sheds light-weight on the sales growth of the various regional and country-level markets. Regionally, this report categorizes the production, apparent consumption, export and import of the global market. Later, the global Cell Therapy Technologies market by each region is later sub-segmented by respective countries and segments. It also provides market size and forecast estimates from the year 2015 to 2026 with respect to five major regions, namely North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Important types of products covered in this report are: Equipment, Consumables, Others

Important applications covered in this report are: Human, Animal,

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/30084/global-cell-therapy-technologies-market-2020-by-manufacturers-countries-type-and-application-forecast-to-2026

Moreover, for the end user/applications the report concentrates on the status and viewpoint for prominent applications/end users, consumption, market share, and development rate for each application. This research document will give all of you the realities about the past, present, and eventual future of the concerned global Cell Therapy Technologies market for 2020 to 2026 time-period. Industrial chain analysis, manufacturing cost structure analysis, and key raw materials analysis of the global market has been given further. In the end section, this report comprises the conclusion and findings of the research study on the global market.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Other Related Reports Here :

Global Lithium-Ion Battery Anode Material Market 2020 Growth Analysis by Key Players, Globally Effective Factors, Trends, Business Plans and Forecast to 2026

Global In-Car HMI/OSS Market 2020 Industry Status and Outlook, Competitive Landscape and Growth by 2026

Global In-Vehicle Thin Film Transistor Liquid Crystal Display (TFT-LCD) Market 2020 by Key Players, Regions, Type and Application, Forecast to 2026

Global Idling Stop Systems Market 2020 Status and Outlook, Industry Growth Rate, Opportunities and Challenges to 2026

Global In-Car HMI/Driver Monitoring Market 2020 Key Players Data, Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2026

Continue reading here:
Global Cell Therapy Technologies Market 2020 by Manufacturers, Countries, Type and Application, Forecast to 2026 - Cheshire Media

Global Animal Cell Culture Market Report presents detailed analysis of Animal Cell Culture industry on the basis of the regions by growth, product types and applications, over the forecast period (2020-2027) of the Animal Cell Culture market. It analyzes every majorfacet of the global Animal Cell Culture by specifications of the product, restraints, challenges, andgrowth opportunities. Company profiles of the major leading player with Animal Cell Culture investment forecast, latest technology trends,and future forecast. The detailed knowledge of the Animal Cell Culture market on a international scale on the basis of current and future size(revenue) and Animal Cell Culture market forecast plot in the form of list of graphs and tables, pie-charts to help aspirants and leading Animal Cell Culture market players in making important and growth decisions.

The Global Animal Cell Culture market reportcomprises variouskey manufacturers, application analysis and type analysis:

List Of Key Players

Corning (Cellgro)Sigma-AldrichCellGenixPromoCellGE HealthcareLife TechnologiesMerck MilliporeZenbioLonzaBDThermo FisherAtlanta BiologicalsHiMediaTakara

Animal Cell Culture Market Segmentation: By Types

Classical Media & SaltsSerum-free MediaStem Cell Media

Animal Cell Culture Market Segmentation: By Applications

Biopharmaceutical ManufacturingTissue Culture & EngineeringGene TherapyCytogenetic

Request For Free Sample Pdf Report + All Related Graphs & [emailprotected] https://www.reportspedia.com/report/chemicals-and-materials/2015-2027-global-animal-cell-culture-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/64669#request_sample

The research mainly covers Animal Cell Culture market in North America (United States, Canada and Mexico), Animal Cell Culture Europe industry (Germany, France, UK, Russia and Italy), Asia-Pacific (Southeast Asia, China, Korea, India and Japan), Animal Cell Culture South America industry (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). The Animal Cell Culture report also performs SWOT (Strengths, Weaknesses, Opportunities, and Threats) with XX CAGR values, and XX USD of past(2015-2019) and Animal Cell Culture forecast(2020-2027) on the basis of growth and market condition following with the size of Animal Cell Culture market.

Get Upto 30% off on this reports at this Black Friday. Ask For Discount @:

https://www.reportspedia.com/discount_inquiry/discount/64669

Later, the report also delivers different segments on basis of Animal Cell Culture product category, plentiful applications of the product and key revenue regions which highly contribute to the Animal Cell Culture market share. The research scrutinizes new growth opportunities, carried out with in-depth analysis of the Animal Cell Culture market on the basis of development, and dataanalysis accounting every aspect of Animal Cell Culture market. Global Animal Cell Culture industry interprets the fundamental aspects of the commanding market players with their business summary, Animal Cell Culture market sales, press release, evolution taking place in the market.

Do yo want any custom data, Inquiry Here For More Details https://www.reportspedia.com/report/chemicals-and-materials/2015-2027-global-animal-cell-culture-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/64669#inquiry_before_buying

Objective:

The research influences different features, of the Animal Cell Culture market. Moreover, it executes the persistent and in-depth study in order to extract global facts and features of Animal Cell Culture market. It analyzes the Animal Cell Culture past and current data and strategizes future Animal Cell Culture market trends. It elaborates the Animal Cell Culture market supply-chain scenario with respect to volume.

It briefs introduction of Animal Cell Culture market business overview, revenue deciding factors and Animal Cell Culture benefits. The research findings mentioned in the Animal Cell Culture report helps Up-stream and Down-stream analysis to measure accomplishment in Animal Cell Culture industry and expansion to take vital decisions in future.

chapter 1 Global Animal Cell Culture Market Industry Overview(Animal Cell Culture Industry, Market Segment, Cost Analysis), upstream and downstream market segmentation, and the cost analysischapter 2 Global Animal Cell Culture Market Industry Environment(Policy, Economics)chapter 3 Global Animal Cell Culture Market By Type(Segment Overview, Market Size, Market Forecast)chapter 4 Global Animal Cell Culture Market Top Key Vendorschapter 5, 6 Global Animal Cell Culture Market Competition (Company Competition) and Animal Cell Culture Market Demand Forecastchapter 7 Global Animal Cell Culture Market Key Analysis of Output, Market and Forecast by Regionwise i.e Europe,South America etc..chapter 8 Global Animal Cell Culture Market Trend Analysis, Regional Market Trend, Market Trend by Product, Market Trend by Application ;chapter 9 The Consumers Analysis of Animal Cell Culture Market(Sales Revenue, Price, Gross Margin)chapter 10 Global Animal Cell Culture Market Research Findings and Conclusion, Appendix, methodology and data source;

Browse Detailed Table Of [emailprotected] https://www.reportspedia.com/report/chemicals-and-materials/2015-2027-global-animal-cell-culture-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/64669#table_of_contents

Contact Us:

Company Name: Globalmarketers.biz

Contact Person: Alex White

Email: [emailprotected]

Phone: +1(617)2752538

Follow this link:
Global Animal Cell Culture Market Professional Survey 2019 by Manufacturers, Regions, Types and Applications, Forecast to 2027 by Reportspedia -...

The globalSeed Treatment Fungicides research reportis the result of a detailed evaluation and a wide-ranging scrutiny of real-world data gathered from the global Seed Treatment Fungicides market. This latest report entails all the significant aspects and present market size of theglobal Seed Treatment Fungicides market. It puts forth point by point examination of the market anchored on the comprehensive study of the several factors such as development situation, market size, potential opportunities, trend analysis, and competitive landscape. The current COVID-19 pandemic impact on the global Seed Treatment Fungicides market is included in the report. The effect of the novel coronavirus outbreak on market development also analyzed and depicted in the report.

Request for FREE SAMPLE REPORT of Seed Treatment Fungicides Market:https://www.syndicatemarketresearch.com/sample/seed-treatment-fungicides-market

(The sample of the report is immediately accessible on request).

Benefits of Asking a FREE PDF Sample Before Buying:

(Note: The report will be updated with COVID-19 impact analysis before delivery)

The leading players [Bayer Cropscience, BASF, Syngenta, Dow Chemical Company, DuPont, Nufarm, FMC Corporation, Novozymes, Platform Specialty Products, Sumitomo Chemical Company, Adama Agricultural Solutions, Arysta Lifescience, UPL] competing in the global Seed Treatment Fungicides market are also included in the report sharing data about manufactures, suppliers, companies, and organizations. The report encompasses company synopsis, profile, product specifications, total revenue (financials), market potential, global status quo, sales &revenue generated, price, share, SWOT analysis, production sites & facilities, and product launch.

In addition, the research offers revenue, sales, and market share during the forecast period for everyplayer included in this Seed Treatment Fungicides report. Further, it entails information about diverse industries clients that are crucial for the manufacturers along with the key merger & acquisitions, collaborations, business policies, and trending innovation.

Make an Inquiry before buying Seed Treatment Fungicides report @https://www.syndicatemarketresearch.com/inquiry/seed-treatment-fungicides-market

(We customize your report as per your need. Ask our sales team for report customization.)

The Seed Treatment Fungicides research report assesses the Seed Treatment Fungicides market with a comprehensive approach by jotting down the major factors drivers, restraints, challenges, risks, and opportunities that are foreseeable to have a noteworthy impact on the growth during the forecast period. The analysis also divides the global market based on various segments such as industry segment, type segment, service/product segment, channel segment, application segment, and so on. The sub-segments (if applicable) are also covered within the analysis.

By Type, the market can be split into

Seed Dressing Fungicides, Seed Coating Fungicides, Seed Pelleting Fungicides, Others

By Application, the market can be split into

Cereals & Grains, Oilseeds & Pulses, Others

The report sheds light on market size, in terms of value & volume, growth potential, current status, and other pertinent data about every segment and sub-segment included in the report. In addition, the report also entails the regional analysis of the global Seed Treatment Fungicides market comprising the leading region, growth factors & opportunities, and forecast for every region and country.

The regions covered in this report include;

Key Highlights of the Report:

The Seed Treatment Fungicides market research report presents an all-inclusive evaluation of numerous business aspects such as recent technological advancements, global market trends, size, market shares, and latest innovations. Apart from this, this systematic information has been collected through data exploratory methods like primary and secondary research. Furthermore, a skilled team of analysts highlights numerous dynamic and static aspects of the global Seed Treatment Fungicides market.

Browse Full Report with TOC @https://www.syndicatemarketresearch.com/market-analysis/seed-treatment-fungicides-market.html

Reasons to buy the global Seed Treatment Fungicides market report:

Read also :https://adalidda.com/posts/oisGfz5icqaEt8TrB/global-stem-cell-therapy-for-diabetes-and-related-conditions

The final report will also be including a dedicated section for the impact of the COVID-19 pandemic on the growth of the Seed Treatment Fungicides market along with future predictions. Also, our team will be available for any kind of assistance to our clients around the clock.

As per your requirement,Syndicate Market Researchpresents the customization of reports. This report can be embodied to satisfy your needs. Contact our sales team (sales@syndicatemarketresearch.com), who will assure you to get a report that satisfies your requirements.

View original post here:
Global Seed Treatment Fungicides Market 2020 Size Share Upcoming Trends Segmentation And Forecast To 2025 - The Courier

Regenerative medicine is a rapidly growing but still largely experimental field that takes a new approach to treating disease. It attempts to restore health by rejuvenating, repairing or replacingdamaged or degenerating cells, tissues and organs. The goal is to restore form and function by relying on the body's ability to heal itself. The potential to find cures, improve care outcomes and boost quality of life stretches to a vast menu of opportunities throughout the body and throughout life. The tools to reach these goals are diverse. They're often based on various types of stem cells. These are special cells that can divide and multiply to produce any type of the more specialized cells in the body, and can be coaxed to promote body healing.

Principles of regenerative medicine are already being used in medical practice with improvements in bone marrow transplantation, treatment for some cancers and early prevention of congenital lung deformities even before birth. Researchers and doctors are developing regenerative medicine techniques to ensure better ways to treat a range of medical problems including heart disease, arthritis, diabetes, stroke and dementia.

Significant investment is fueling the growth of regenerative science and its application in medical care. Mayo Clinic has established a Center for Regenerative Medicine. The National Institutes of Health, with funding from Congress, has established the Regenerative Medicine Innovation Project. Still, the field is young and most related work happens in the laboratory or in clinical trials rather than in a hospital bed. The ethical dimensions of implementing...

Read more from the original source:
Regenerative medicine - Mayo Clinic

Sanford Health a history of innovating and leading the way in new research.

Something that grabbed the attention of the NFL Alumni Association.

The NFL Alumni Association is a non-profit that looks to support retired NFL athletes and cheerleaders after their initial careers are over.

Because of the strenuous activity put on their bodies, many athletes walk away from the sport with nagging injuries without the option for care. This has led the NFL Alumni to seek out innovators in the world of health care.

Recently, Dr. David Pearce, Sanford Health president for innovation, research and World Clinic, spoke on regenerative medicine at a congressional briefing. His expertise prompted Kyle Richardson and Billy Davis, co-directors of health care initiatives for the NFL Alumni Association, to inquire about regenerative medicine and how it may serve retired athletes.

More: NFL Alumni tour Sanford, discuss regenerative medicine

As Dr. Pearce told Sanford Health News, its a complicated term, but regenerative medicine is essentially about healing. Dr. Pearce explains that regenerative healing takes something from your own body to heal a wound or an injury.

Im going to give you an example: if you cut yourself right now, it heals, right? The components within your body have the ability to heal an injury, such as a cut. If we twist our ankle and we get swelling, our body reacts and heals that injury. Regenerative medicine is about accelerating that healing so, taking a component of your body, and accelerating that healing and making it better.

Not only for retired athletes, this form of therapy could benefit everyone as they age.

As we get older, we start to deteriorate. So, we can harness our own body to maybe take some of those components that would be used to fix an injury to actually slow down the aging process and the wear and tear on joints, partiucularly in orthopedics.

Thats one of the highlighted areas that we are studying right now. As your knees grind away and you get arthritis, regenerative medicine is about taking some of those healing components to help regenerate and slow down that process, to heal those aches and pains, said Dr. Pearce.

Tiffany Facile is a research development partner at Sanford Health, and soon-to-be director of regenerative medicine at Sanford Health.

She says its imperative this medicine develops through the science of clinical trials.

Some common misconceptions are that regenerative medicine therapies are risky. There is some risk to procedures when using autologous or your own cells, but studies that are currently running should reduce the safety concerns.

Dr. Pearce echos Facile, warning of bad actors who offer products which have no regenerative capacity.

He says theres also a misconception associated with these therapies because theyre not approved by the FDA. However, Sanford Healths clinical trials have been approved.

What were doing at Sanford, is were taking those components of the body, working with the FDA and saying, its safe to do this. Our early work in a clinical study has demonstrated safety and efficacy with rotator cuff injuries. Were having remarkable results in terms of treating some of these injuries.

Another misconception revolves around stem cells. Both Facile and Dr. Pearce say regenerative medicine has not yet determined if stem cells in your body have the ability to signal other cells for repair.

We hear about embryonic stem cells and fetal stem cells; we dont do anything with that. First of all, its not very ethical. Secondly, theres no science to show that they can have regenerative capabilities, said Dr. Pearce.

Dr. Pearce says regenerative medicine can be used to heal nagging injuries, whether its for athletes or not.

Right now were taking cells from around the fat of your abdomen region, which is rich in a type of stem cell called adipose derived regenerative cells, and were relocating them to help heal rotator cuff tears, help to heal osteoarthritis in the knee, elbow, wrist, ankle, and hip, he said.

Dr. Pearce says theyre doing this research, under the auspices of what we call a clinical trial, and where we follow patients to hopefully demonstrate safety and efficacy.

Because of the misconceptions surrounding this form of medicine, we have to do this right, because its not a regulated industry just yet. The food and drug administration oversees what were doing with respect to that.

We know that we can help heal damaged heart cells. We know we can help healing cells that have been damaged by a stroke. Were already taking the next step in working on those protocols where we can do some trials and look to see if we can heal other injuries in the body. These cells have the ability to heal anything in the body, if directed in the right way, said Dr. Pearce.

Dr. Pearce says Sanford Health is the first health system in the nation to get approval for the use of regenerative medicine in treating orthopedic injuries.

Were hoping to be a leader not just in the Midwest, were hoping to be a leader nationally, where we can teach other health systems how to administer these treatments by either going there and training people, or us becoming really a hub for that.

As for the future of regenerative medicine, Dr. Pearce says it could have an impact in how quickly athletes recover from injuries.

I think for athletes that return to play, this will have a huge impact in terms of how we can help people turn around. More importantly, as they retire, we know theres a lot of grinding and wear and tear on their bodies. Well be able to manage that much more appropriately, said Dr. Pearce.

This form of medicine can also help non-athletes manage any nagging aches and pains.

For those whove got some aches and pains here and there, well be able to use this to really alleviate some of the pain and aches we have, and manage that much better.

Posted In Innovations, Orthopedics, Research, Specialty Care, Sports Medicine, World Clinic

Read more from the original source:
What is regenerative medicine? - Sanford Health News

Regenerative medicine, the application of treatments developed to replace tissues damaged by injury or disease. These treatments may involve the use of biochemical techniques to induce tissue regeneration directly at the site of damage or the use of transplantation techniques employing differentiated cells or stem cells, either alone or as part of a bioartificial tissue. Bioartificial tissues are made by seeding cells onto natural or biomimetic scaffolds (see tissue engineering). Natural scaffolds are the total extracellular matrixes (ECMs) of decellularized tissues or organs. In contrast, biomimetic scaffolds may be composed of natural materials, such as collagen or proteoglycans (proteins with long chains of carbohydrate), or built from artificial materials, such as metals, ceramics, or polyester polymers. Cells used for transplants and bioartificial tissues are almost always autogeneic (self) to avoid rejection by the patients immune system. The use of allogeneic (nonself) cells carries a high risk of immune rejection and therefore requires tissue matching between donor and recipient and involves the administration of immunosuppressive drugs.

A scientist conducting research on stem cells.

A variety of autogeneic and allogeneic cell and bioartificial tissue transplantations have been performed. Examples of autogeneic transplants using differentiated cells include blood transfusion with frozen stores of the patients own blood and repair of the articular cartilage of the knee with the patients own articular chondrocytes (cartilage cells) that have been expanded in vitro (amplified in number using cell culture techniques in a laboratory). An example of a tissue that has been generated for autogeneic transplant is the human mandible (lower jaw). Functional bioartificial mandibles are made by seeding autogeneic bone marrow cells onto a titanium mesh scaffold loaded with bovine bone matrix, a type of extracellular matrix that has proved valuable in regenerative medicine for its ability to promote cell adhesion and proliferation in transplantable bone tissues. Functional bioartificial bladders also have been successfully implanted into patients. Bioartificial bladders are made by seeding a biodegradable polyester scaffold with autogeneic urinary epithelial cells and smooth muscle cells.

Another example of a tissue used successfully in an autogeneic transplant is a bioartificial bronchus, which was generated to replace damaged tissue in a patient affected by tuberculosis. The bioartificial bronchus was constructed from an ECM scaffold of a section of bronchial tissue taken from a donor cadaver. Differentiated epithelial cells isolated from the patient and chondrocytes derived from mesenchymal stem cells collected from the patients bone marrow were seeded onto the scaffold.

There are few clinical examples of allogeneic cell and bioartificial tissue transplants. The two most common allogeneic transplants are blood-group-matched blood transfusion and bone marrow transplant. Allogeneic bone marrow transplants are often performed following high-dose chemotherapy, which is used to destroy all the cells in the hematopoietic system in order to ensure that all cancer-causing cells are killed. (The hematopoietic system is contained within the bone marrow and is responsible for generating all the cells of the blood and immune system.) This type of bone marrow transplant is associated with a high risk of graft-versus-host disease, in which the donor marrow cells attack the recipients tissues. Another type of allogeneic transplant involves the islets of Langerhans, which contain the insulin-producing cells of the body. This type of tissue can be transplanted from cadavers to patients with diabetes mellitus, but recipients require immunosuppression therapy to survive.

Cell transplant experiments with paralyzed mice, pigs, and nonhuman primates demonstrated that Schwann cells (the myelin-producing cells that insulate nerve axons) injected into acutely injured spinal cord tissue could restore about 70 percent of the tissues functional capacity, thereby partially reversing paralysis.

Studies on experimental animals are aimed at understanding ways in which autogeneic or allogeneic adult stem cells can be used to regenerate damaged cardiovascular, neural, and musculoskeletal tissues in humans. Among adult stem cells that have shown promise in this area are satellite cells, which occur in skeletal muscle fibres in animals and humans. When injected into mice affected by dystrophy, a condition characterized by the progressive degeneration of muscle tissue, satellite cells stimulate the regeneration of normal muscle fibres. Ulcerative colitis in mice was treated successfully with intestinal organoids (organlike tissues) derived from adult stem cells of the large intestine. When introduced into the colon, the organoids attached to damaged tissue and generated a normal-appearing intestinal lining.

In many cases, however, adult stem cells such as satellite cells have not been easily harvested from their native tissues, and they have been difficult to culture in the laboratory. In contrast, embryonic stem cells (ESCs) can be harvested once and cultured indefinitely. Moreover, ESCs are pluripotent, meaning that they can be directed to differentiate into any cell type, which makes them an ideal cell source for regenerative medicine.

Studies of animal ESC derivatives have demonstrated that these cells are capable of regenerating tissues of the central nervous system, heart, skeletal muscle, and pancreas. Derivatives of human ESCs used in animal models have produced similar results. For example, cardiac stem cells from heart-failure patients were engineered to express a protein (Pim-1) that promotes cell survival and proliferation. When these cells were injected into mice that had experienced myocardial infarction (heart attack), the cells were found to enhance the repair of injured heart muscle tissue. Likewise, heart muscle cells (cardiomyocytes) derived from human ESCs improved the function of injured heart muscle tissue in guinea pigs.

Derivatives of human ESCs are likely to produce similar results in humans, although these cells have not been used clinically and could be subject to immune rejection by recipients. The question of immune rejection was bypassed by the discovery in 2007 that adult somatic cells (e.g., skin and liver cells) can be converted to ESCs. This is accomplished by transfecting (infecting) the adult cells with viral vectors carrying genes that encode transcription factor proteins capable of reprogramming the adult cells into pluripotent stem cells. Examples of these factors include Oct-4 (octamer 4), Sox-2 (sex-determining region Y box 2), Klf-4 (Kruppel-like factor 4), and Nanog. Reprogrammed adult cells, known as induced pluripotent stem (iPS) cells, are potential autogeneic sources for cell transplantation and bioartificial tissue construction. Such cells have since been created from the skin cells of patients suffering from amyotrophic lateral sclerosis (ALS) and Alzheimer disease and have been used as human models for the exploration of disease mechanisms and the screening of potential new drugs. In one such model, neurons derived from human iPS cells were shown to promote recovery of stroke-damaged brain tissue in mice and rats, and, in another, cardiomyocytes derived from human iPS cells successfully integrated into damaged heart tissue following their injection into rat hearts. These successes indicated that iPS cells could serve as a cell source for tissue regeneration or bioartificial tissue construction.

See the original post:
regenerative medicine | Definition, Stem Cells, & Facts ...

LONDON--(BUSINESS WIRE)--Increasing investment in R&D, and a steady rise in the prevalence of chronic diseases, has fueled demand for regenerative medicine. Additionally, the upsurge in M&A alliances and strategic partnerships has significantly propelled growth in regenerative medicine. However, there are various challenges with regenerative medicine manufacturing, including high and rising manufacturing expenses, the quality of designs, issues with supply chain and biomaterials.

Request a free proposal to know how Infiniti is supporting the regenerative medicine market to overcome the pressing manufacturing challenges.

The regenerative medicine market has significant benefits for big pharma and is expected to grow significantly. Experts expect a rapid pace of development in the regenerative medicine market over the next decade. The increasing investments in R&D activities and the rising incidence of chronic diseases in the US are key factors in fueling demand. Further, strategic alliances among vendors will have a significant impact on the overall market growth and innovation. Several roadblocks to commercially viable therapies have made it challenging to deliver regenerative medicines. In their latest article, Infinitis industry analysts highlight some of the most critical and pressing manufacturing challenges in regenerative medicine products.

Regenerative medicine is currently the hive of innovation in modern science with far-reaching benefits for big pharma, healthcare systems, and patient outcomes. We can expect a rapid pace of development in the US regenerative medicine market over the next decade, says a product development strategy expert at Infiniti Research.

Infinitis industry analysts highlighted the following four key challenges in the regenerative medicine market:

Speak with our industry experts for more insights on the major challenges in the regenerative medicine market and how companies can capitalize on the forecasted growth.

About Infiniti Research

Established in 2003, Infiniti Research is a leading market intelligence company providing smart solutions to address your business challenges. Infiniti Research studies markets in more than 100 countries to help analyze competitive activity, see beyond market disruptions, and develop intelligent business strategies. To know more, visit: https://www.infinitiresearch.com/about-us

See the original post:
What Pressing Challenges Does the Pharmaceutical Industry Face with Regenerative Medicine Manufacturing? Infiniti's Industry Analysts Highlight and...

Share This Article:A stem cell research center at UC Davis. Courtesy California Institute for Regenerative MedicineBy Barbara Feder Ostrov | CalMatters

Californias stem cell research agency was supposed to be winding down its operations right about now, after a 16-year run and hundreds of millions in grants to scientists researching cutting-edge treatments for diabetes, cancer, Alzheimers and other diseases.

Support Times of San Diego's growthwith a small monthly contribution

Instead, the taxpayer-supported California Institute for Regenerative Medicine will get a $5.5 billion reboot after voters earlier this month narrowly passed the Proposition 14bond measure. The overall cost of the bonds with interest will total about $7.8 billion.

Were thrilled that California voters saw fit to continue the work weve done, said Jonathan Thomas, chair of the agencys governing board. California has always had a frontier mentality and a love for the cutting edge, and the work that CIRM has done has put it on the very forefront of regenerative medicine.

Even with Californias economy in a coronavirus-induced tailspin and somescientists arguingthat stem cell research no longer needs taxpayer support,Prop. 14passed with 51 percent of the vote after well-financed supporters pourednearly $21 millioninto the Yes on 14 campaign. The measure was essentially a rerun of Proposition 71, which California voters approved in 2004 after a since-revoked federal ban on embryonic stem cell research.

The cash infusion is expected to keep the institute running for another 10 to 15 years, although the agency will see some significant changes under Prop. 14.

The institute also must contend with longstanding concerns over conflicts of interest that have dogged it since its inception, observers say. About 80% of the money distributed has gone to universities and companies tied to agency board members, according to an analysisby longtime agency watchdog David Jensen, a former Sacramento Bee journalist who runs theCalifornia Stem Cell Reportblog and wrote abookon the institute.

Prop. 14 allows the agency to fund a wider array of research projects even some that dont involve stem cells, but instead are related to genetics, personalized medicine and aging.

Thats necessary because the field has evolved, said Paul Knoepfler, a UC Davis professor of cell biology who studies the role of stem cells in cancer and writes a stem cell blog. He received a 2009 grant from the institute.

Stem cells are interesting and important, but there are going to be a lot of new therapies in the next 10 years that are not stem-cell centric, Knoepfler said.

Other changes for the agency include:

Ysabel Duron, who joined the institutes board late last year, said she sees her role as promoting equity in opportunities for both researchers and patients and ensuring that treatments resulting from the research can benefit all Californians.

Researchers in particular need to boost the diversity of patients in their clinical trials and do a better job communicating the value of their work to the public, Duron said, noting that nearly 40% of Californians are Latino.

We need to keep researchers feet to the fire, said Duron, a former television journalist and founder of the Latino Cancer Institute. They need to show us a plan and we need to reward them.

To date, the agency has funded 64 clinical trials of treatments for many types of cancer, sickle cell disease, spinal cord injuries, diabetes, kidney disease and amyotrophic lateral sclerosis, commonlyknown as Lou Gehrigs disease.But the most advanced trials involve therapies for relatively rare conditions, such asSevere Combined Immunodeficiency known as the bubble baby disease, Jensen noted. That therapy is being reviewed by the FDA but has not yet been approved.

Cancer, heart disease these are the big killers. Thats what most people are interested in, Jensen said. You can fund something for a rare disease, but that doesnt affect the majority of Californians.

And, Jensen asks, what will happen after the agency runs out of money again? Will taxpayers once again be asked to refill its coffers? There was hope when the agency began that revenues from successful treatments would sustain its grant-making in the years to come, but the institute has only received a few hundred thousand dollars, not nearly enough to become self-sustaining without taxpayer support, according to theLegislative Analysts Office.

The sustainability issue is important and its hard to address, Jensen said. The money doesnt last forever.

Stem Cell Medical Research to Expand in California Following Passage of Prop. 14 was last modified: November 27th, 2020 by Editor

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Here is the original post:
Stem Cell Medical Research to Expand in California Following Passage of Prop. 14 - Times of San Diego

Researchers at Stanford Burnham Prebys Medical Discovery Institute recently developed a drug that can lure stem cells to impaired tissue and enhance the efficacy of treatment.

This is considered a "scientific first," not to mention a major advance for the field of regenerative drugs. Such a discovery, which theProceedings of the National Academy of Sciences or PNASpublished could enhance the present stem cell treatments developed to cure such neurological disorders like stroke, spinal cord injury, ALS or other amyotrophic lateral sclerosis, as well as other neurodegenerative diseases -- and have their use expanded to new conditions such as arthritis or heart disease.

In the study, toxic or green cells disappeared when mice with a neurodegenerative condition were given both therapeutic or red cells and the drug SDV1a, which matched with delayed onset of symptoms and longer lives.

(Photo : Stem Cell Research via Getty Images)In this undated handout photo released by the Institute for Stem Cell Research in 2005, neurons (red) and astrocytes (green), which can be made from neural stem cells, are seen.

Results Suggesting Efficacy of the Drug

The study results proposed that SDV1a can be used to enhance the stem cell treatments' efficacy. According to Evan Snyder, MD, PhD, theCenter for Stem Cells & Regenerative Medicine at Stanford Burnham Prebysprofessor and director, "the ability to instruct a stem cell where to go in the body, or to a particular region of a given organ is the 'Holy Grail' for regenerative medicine.

Snyder, who's also the senior author of the study, added, now, for the first time, stem cells can be directed to a desired area and focus its therapeutic effect.

Almost a decade-and-a-half back, the senior author, together with his team, found that stem cells are drawn to infection, a biological 'fire alarm' indicating that damage has taken place.

Nevertheless, using inflammation as a healing appeal is not possible since an inflammation environment can be dangerous to the body. Hence, researchers have been searching for mechanisms to help in the migration of stem cells or 'home' to the body's desired areas.

Such a mechanism or tool, according to reports on this new finding, would be a great contributor for disorders in which preliminary inflammatory indicators disappear over time, like chronic spinal cord injury or stroke, and conditions where the inflammation's role is not clearly understood, like heart disease, for one.

Fortunately, after decades of investing in stem cell science, scientists are now making "tremendous progress," saidCalifornia Institute for Regenerative Medicine or CIRMpresident and CEO Maria Millan, MD said, in their understanding of the manner such cells work and the manner they can be attached to help reverse disease or an injury.

The CIRM partially funded this new study. Millan also said, Snyder's group has identified a medicine that could enhance "the ability of neural stem cells to home to sites of injury and initiate repair."

More so, the president and CEO also explained, the drug candidate could help fast-track the stem cell treatments' development, specifically for conditions including Alzheimer's disease and spinal cord injury.

In the research, study investigators modified an inflammatory molecule called CXCL12, which the Snyder's group discovered previously, could guide healing stem cells to areas that need repair to develop the SDV1a.

As such, this new medicine works by improving stem cell binding and minimizing inflammatory indicating and can be injected anywhere to attract stem cells to a particular site without causing any inflammation.

Since such inflammation can be dangerous, Snyder explained, they modified CXL12 by "tripping away the risky beat and maximizing the good bit."

Now, he added, they have a drug, drawing stem cells to an area of pathology, but not creating or worsening the unwanted infection.

"Now, we have a drug that draws stem cells to a region of pathology, but without creating or worsening unwanted inflammation."

Furthermore, to present that the new medication can improve the effectiveness of stem cell therapy, the scientists implanted SDV1a and human neural stem cells into the brains of mice thatSandhoff disease, a neurodegenerative disease.

The scientists have already started testing the ability of SDV1a to enhance stem cell therapy in a mouse model of Lou Gehrig's disease, also known as ALS, which results from progressive loss of motor neurons in the brain.

Snyder said they are optimistic that the mechanism of action of this new drug may potentially benefit various neurodegenerative disorders and non-neurological conditions like arthritis, heart disease, and even brain cancer.

Interestingly, he also explained, since CXL12 and its receptor is said to be implicated in cytokine storm that exemplifies severeCOVID-19, some of their understandings of how to constrain infection without controlling other normal procedures selectively may be helpful in that field, as well.

RELATED:'Marie Kondo' Protein in Fruit Fly Embryos Helps Them Keep Organized

Check out more news and information onStem Cellsin Science Times.

Original post:
Scientists Reveal a New Drug That Directs Stem Cells To Desired Sites - Science Times

Telomeres are the protective caps at chromosome ends. In adult cells, telomeres shorten each time a cell divides and this contributes to ageing and cancer. Pluripotent stem cells, however, are specialised cells that exist in the earliest days of development. These pluripotent cells do not age and have the ability to turn into any type of adult cell.

The surprise finding, published today in Nature, shows that telomeres in pluripotent stem cells are protected very differently than telomeres in adult tissues.

This upends 20 years of thinking on how stem cells protect their DNA, said Associate Professor Tony Cesare, from the University of Sydneys Faculty of Medicine and Health, who is Head of the Genome Integrity Unit at Childrens Medical Research Institute (CMRI) and co-leader of a research team that collaborated on this research.

In adult cells, a protein called TRF2 is essential because it arranges DNA at the chromosome end into a telomere-loop structure. Removing TRF2 from adult cells causes the chromosomes to become stitched together into one long string, which is incompatible with life.

To the researchers astonishment, removing TRF2 from pluripotent stem cells did almost nothing. The chromosomes were normal, the telomere-loops remained, and the cells divided as if nothing happened. Telomeres are therefore protected differently in pluripotent stem cells and adult tissues.

This unexpected finding has major implications for research on ageing, human development, regenerative medicine, and cancer. Previously, researchers expected fundamental mechanisms that protected DNA would be the same in all tissues. This now appears to be incorrect.

View original post here:
Unexpected discovery about stem cell immortality study - News - The University of Sydney

Orthopedic Regenerative Medicine Market

Coherent Market Insights, 26-11-2020: The research report on the Orthopedic Regenerative Medicine Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Get a sample pages of this Report:https://www.coherentmarketinsights.com/insight/request-sample/3566

The segments and sub-section of Orthopedic Regenerative Medicine market are shown below:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Some of the key players/Manufacturers involved in the Orthopedic Regenerative Medicine Market are Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

If opting for the Global version of Orthopedic Regenerative Medicine Market analysis is provided for major regions as follows:

North America (The US, Canada, and Mexico)

Europe (the UK, Germany, France, and Rest of Europe)

Asia Pacific (China, India, and Rest of Asia Pacific)

Latin America (Brazil and Rest of Latin America)

Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)

Buy This Complete A Business Report @:https://www.coherentmarketinsights.com/insight/buy-now/3566

The Orthopedic Regenerative Medicine Market Report Consists of the Following Points:

The report consists of an overall prospect of the market that helps gain significant insights about the global market.

The market has been categorized based on types, applications, and regions. For an in-depth analysis and better understanding of the market, the key segments have been further categorized into sub-segments.

The factors responsible for the growth of the market have been mentioned. This data has been gathered from primary and secondary sources by industry professionals. This provides an in-depth understanding of key segments and their future prospects.

The report analyses the latest developments and the profiles of the leading competitors in the market.

The Orthopedic Regenerative Medicine Market research report offers an eight-year forecast.

Enquire for customization in Report @https://www.coherentmarketinsights.com/insight/request-customization/3566

Interested about who is winning the race of COVID-19 Vaccine. Coherent Market Insights (CMI)

providesCOVID-19 Vaccine Trackerfor all the latest updates about COVID-19 Vaccine.

CMI also offers Custom Research services providing focused, comprehensive and tailored research according to clientele objectives. Thanks for reading this article; you can also get individual chapter wise section or region wise report like North America, Europe or Asia.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us:Direct Line: +1-206-701-6702 (US)Web:https://www.coherentmarketinsights.com

See the article here:
Impact of COVID 19 on Orthopedic Regenerative Medicine Market Detailed Research Study 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation,...

NEW YORK, Nov. 25, 2020 /PRNewswire/ --Amid the COVID-19 crisis, the global market for Cell Harvesting estimated at US$233.2 Million in the year 2020, is projected to reach a revised size of US$381.4 Million by 2027, growing at a CAGR of 7.3% over the period 2020-2027.Manual, one of the segments analyzed in the report, is projected to grow at a 7.9% CAGR to reach US$284.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Automated segment is readjusted to a revised 5.6% CAGR for the next 7-year period. This segment currently accounts for a 28.3% share of the global Cell Harvesting market.

Read the full report: https://www.reportlinker.com/p05798117/?utm_source=PRN

The U.S. Accounts for Over 30.9% of Global Market Size in 2020, While China is Forecast to Grow at a 10.4% CAGR for the Period of 2020-2027

The Cell Harvesting market in the U.S. is estimated at US$72 Million in the year 2020. The country currently accounts for a 30.86% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$34.9 Million in the year 2027 trailing a CAGR of 10.4% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.1% and 7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR while Rest of European market (as defined in the study) will reach US$34.9 Million by the year 2027.We bring years of research experience to this 5th edition of our report. The 226-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05798117/?utm_source=PRN

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1

II. EXECUTIVE SUMMARY II-1

1. MARKET OVERVIEW II-1 Cell Harvesting - A Prelude II-1 Impact of Covid-19 and a Looming Global Recession II-1 With Stem Cells Holding Potential to Emerge as Savior for Healthcare System Struggling with COVID-19 Crisis, Demand for Cell Harvesting to Grow II-1 Select Clinical Trials in Progress for MSCs in the Treatment of COVID-19 II-2 Lack of Antiviral Therapy Brings Spotlight on MSCs as Potential Option to Treat Severe Cases of COVID-19 II-3 Stem Cells Garner Significant Attention amid COVID-19 Crisis II-3 Growing R&D Investments & Rising Incidence of Chronic Diseases to Drive the Global Cell Harvesting Market over the Long-term II-3 US Dominates the Global Market, Asia-Pacific to Experience Lucrative Growth Rate II-4 Biopharmaceutical & Biotechnology Firms to Remain Key End-User II-4 Remarkable Progress in Stem Cell Research Unleashes Unlimited Avenues for Regenerative Medicine and Drug Development II-4 Drug Development II-5 Therapeutic Potential II-5

2. FOCUS ON SELECT PLAYERS II-6 Recent Market Activity II-7 Innovations and Advancements II-7

3. MARKET TRENDS & DRIVERS II-8 Development of Regenerative Medicine Accelerates Demand for Cell Harvesting II-8 The Use of Mesenchymal Stem Cells in Regenerative Medicine to Drive the Cell Harvesting Market II-8 Rise in Volume of Orthopedic Procedures Boosts Prospects for Stem Cell, Driving the Cell Harvesting II-9 Exhibit 1: Global Orthopedic Surgical Procedure Volume (2010- 2020) (in Million) II-11 Increasing Demand for Stem Cell Based Bone Grafts: Promising Growth Ahead for Cell Harvesting II-11 Spectacular Advances in Stem Cell R&D Open New Horizons for Regenerative Medicine II-12 Exhibit 2: Global Regenerative Medicines Market by Category (2019): Percentage Breakdown for Biomaterials, Stem Cell Therapies and Tissue Engineering II-13 Stem Cell Transplants Drive the Demand for Cell Harvesting II-13 Rise in Number of Hematopoietic Stem Cell Transplantation Procedures Propels Market Expansion II-15 Growing Incidence of Chronic Diseases to Boost the Demand for Cell Harvesting II-16 Exhibit 3: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-17 Exhibit 4: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018 II-18 Exhibit 5: Number of New Cancer Cases and Deaths (in Million) by Region for 2018 II-19 Exhibit 6: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others II-19 Exhibit 7: Rising Diabetes Prevalence Presents Opportunity for Cell Harvesting: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045 II-20 Ageing Demographics to Drive Demand for Stem Cell Banking II-20 Global Aging Population Statistics - Opportunity Indicators II-21 Exhibit 8: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 II-21 Exhibit 9: Life Expectancy for Select Countries in Number of Years: 2019 II-22 High Cell Density as Major Bottleneck Leads to Innovative Cell Harvesting Methods II-22 Advanced Harvesting Systems to Overcome Centrifugation Issues II-23 Sophisticated Filters for Filtration Challenges II-23 Innovations in Closed Systems Boost Efficiency & Productivity of Cell Harvesting II-23 Enhanced Harvesting and Separation of Micro-Carrier Beads II-24

4. GLOBAL MARKET PERSPECTIVE II-25 Table 1: World Current & Future Analysis for Cell Harvesting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-25

Table 2: World Historic Review for Cell Harvesting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-26

Table 3: World 15-Year Perspective for Cell Harvesting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 II-27

Table 4: World Current & Future Analysis for Manual by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-28

Table 5: World Historic Review for Manual by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-29

Table 6: World 15-Year Perspective for Manual by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-30

Table 7: World Current & Future Analysis for Automated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-31

Table 8: World Historic Review for Automated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-32

Table 9: World 15-Year Perspective for Automated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-33

Table 10: World Current & Future Analysis for Peripheral Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-34

Table 11: World Historic Review for Peripheral Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-35

Table 12: World 15-Year Perspective for Peripheral Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-36

Table 13: World Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-37

Table 14: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-38

Table 15: World 15-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-39

Table 16: World Current & Future Analysis for Umbilical Cord by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-40

Table 17: World Historic Review for Umbilical Cord by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-41

Table 18: World 15-Year Perspective for Umbilical Cord by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-42

Table 19: World Current & Future Analysis for Adipose Tissue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-43

Table 20: World Historic Review for Adipose Tissue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-44

Table 21: World 15-Year Perspective for Adipose Tissue by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-45

Table 22: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-46

Table 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-47

Table 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-48

Table 25: World Current & Future Analysis for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-49

Table 26: World Historic Review for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-50

Table 27: World 15-Year Perspective for Biotech & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-51

Table 28: World Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-52

Table 29: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-53

Table 30: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-54

Table 31: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-55

Table 32: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-56

Table 33: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-57

III. MARKET ANALYSIS III-1

GEOGRAPHIC MARKET ANALYSIS III-1

UNITED STATES III-1 Increasing Research on Stem Cells for Treating COVID-19 to drive the Cell Harvesting Market III-1 Rising Investments in Stem Cell-based Research Favors Cell Harvesting Market III-1 Exhibit 10: Stem Cell Research Funding in the US (in US$ Million) for the Years 2011 through 2017 III-2 A Strong Regenerative Medicine Market Drives Cell Harvesting Demand III-2 Arthritis III-3 Exhibit 11: Percentage of Population Diagnosed with Arthritis by Age Group III-3 Rapidly Ageing Population: A Major Driving Demand for Cell Harvesting Market III-4 Exhibit 12: North American Elderly Population by Age Group (1975-2050) III-4 Increasing Incidence of Chronic Diseases Drives Focus onto Cell Harvesting III-5 Exhibit 13: CVD in the US: Cardiovascular Disease* Prevalence in Adults by Gender & Age Group III-5 Rising Cancer Cases Spur Growth in Cell Harvesting Market III-5 Exhibit 14: Estimated Number of New Cancer Cases and Deaths in the US (2019) III-6 Exhibit 15: Estimated New Cases of Blood Cancers in the US (2020) - Lymphoma, Leukemia, Myeloma III-7 Exhibit 16: Estimated New Cases of Leukemia in the US: 2020 III-7 Market Analytics III-8 Table 34: USA Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-8

Table 35: USA Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-9

Table 36: USA 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-10

Table 37: USA Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-11

Table 38: USA Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-12

Table 39: USA 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-13

Table 40: USA Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-14

Table 41: USA Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-15

Table 42: USA 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-16

CANADA III-17 Market Overview III-17 Exhibit 17: Number of New Cancer Cases in Canada: 2019 III-17 Market Analytics III-18 Table 43: Canada Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-18

Table 44: Canada Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-19

Table 45: Canada 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-20

Table 46: Canada Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-21

Table 47: Canada Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-22

Table 48: Canada 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-23

Table 49: Canada Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-24

Table 50: Canada Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-25

Table 51: Canada 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-26

JAPAN III-27 Increasing Demand for Regenerative Medicine in Geriatric Healthcare and Cancer Care to Drive Demand for Cell Harvesting III-27 Exhibit 18: Japanese Population by Age Group (2015 & 2040): Percentage Share Breakdown of Population for 0-14, 15-64 and 65 & Above Age Groups III-27 Exhibit 19: Cancer Related Incidence and Deaths by Site in Japan: 2018 III-28 Market Analytics III-29 Table 52: Japan Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-29

Table 53: Japan Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-30

Table 54: Japan 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-31

Table 55: Japan Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-32

Table 56: Japan Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-33

Table 57: Japan 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-34

Table 58: Japan Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-35

Table 59: Japan Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-36

Table 60: Japan 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-37

CHINA III-38 Rising Incidence of Cancer Drives Cell Harvesting Market III-38 Exhibit 20: Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018 III-38 Market Analytics III-39 Table 61: China Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-39

Table 62: China Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-40

Table 63: China 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-41

Table 64: China Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-42

Table 65: China Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-43

Table 66: China 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-44

Table 67: China Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-45

Table 68: China Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-46

Table 69: China 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-47

EUROPE III-48 Cancer in Europe: Key Statistics III-48 Exhibit 21: Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018 III-48 Ageing Population to Drive Demand for Cell Harvesting Market III-49 Exhibit 22: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15- 64, and 65 & Above III-49 Market Analytics III-50 Table 70: Europe Current & Future Analysis for Cell Harvesting by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 III-50

Table 71: Europe Historic Review for Cell Harvesting by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-51

Table 72: Europe 15-Year Perspective for Cell Harvesting by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 III-52

Table 73: Europe Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-53

Table 74: Europe Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-54

Table 75: Europe 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-55

Table 76: Europe Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-56

Table 77: Europe Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-57

Table 78: Europe 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-58

Table 79: Europe Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-59

Table 80: Europe Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-60

Table 81: Europe 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-61

FRANCE III-62 Table 82: France Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-62

Table 83: France Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-63

Table 84: France 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-64

Table 85: France Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-65

Table 86: France Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-66

Table 87: France 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-67

Link:
Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - PRNewswire

DUBLIN, Nov. 25, 2020 /PRNewswire/ -- The "Global Biomaterials Market By Product (Implants, Valves, Joint Replacement, Contact Lenses and Others), By Material Type (Metallic, Natural, Ceramics, Polymeric, Living Cell and Tissue), By Type, By Application, By End User, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Biomaterials Market is expected to register substantial rate of growth during the forecast period owing to factors like increasing geriatric population, rapidly growing healthcare sector and its wider use in various products and applications, such as contact lenses, skin repair, blood vessel prosthesis, gene transfer, drug delivery, and dental.

Biomaterials are artificially derived synthetic or natural materials which are used to interact with biological systems for medical purposes and treatments. They are often used in medical applications to augment or replace a natural function. The biomaterial market is anticipated to grow significantly during the next five years due to discoveries in tissue engineering, regenerative medicine, and more. They often are biodegradable, and some are bio-absorbable, meaning they are eliminated gradually from the body after fulfilling a function. Additionally, metals, ceramics, plastic, glass, and even living cells and tissue all can be used in creating a biomaterial. Moreover, heavy funding by government organizations for innovation of new products is creating new scope for the growth in biomaterials market. Rising prevalence of cardiovascular, neurological, & orthopedic disorders, coupled with increasing awareness regarding the advantages of biomaterials products is further driving the market. Furthermore, rising prevalence of cardiovascular, neurological, & orthopedic disorders around the world is anticipated to create major demand for biomaterials through 2025.

The Global Biomaterials Market is segmented based on product, material type, type, application, end-user, and region. Based on material type, the market is segmented into metallic, natural, ceramics, polymeric, living cell and tissue. The metallic biomaterials segment held lion's share in 2019 due to wide use of metals in the manufacturing of medical devices and their use in orthopedic procedures for bone support and replacement, as they are strong and resistant to fatigue degradation.

By region, North America dominates the biomaterials market owing to the initiatives undertaken by several public and private organizations in the region. Also, factors such as favorable government policies and presence of major market players made the region dominant in terms of revenue share in 2019. However, Asia-Pacific region is expected to register highest CAGR in the coming years due to a large population base in countries like India and China coupled with growing incidences of chronic diseases and rising awareness about biomaterials in the region.

Objective of the Study:

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Biomaterials Market

4. Executive Summary

5. Global Biomaterials Market Outlook5.1. Market Size & Forecast5.1.1. By Value & Volume5.2. Market Share & Forecast5.2.1. By Product (Implants, Valves, Joint Replacement, Contact Lenses and Others)5.2.2. By Material Type (Metallic, Natural, Ceramics, Polymeric, Living Cell and Tissue)5.2.3. By Type (Bioinert, Bioresorbable, Bio Tolerant and Bioactive)5.2.4. By Application (Ophthalmology, Cardiovascular, Orthopedic, Wound Healing, Plastic Surgery, Neurology, Dental, Others)5.2.5. By End User (Private Hospitals, Government Hospitals, Specialty Clinics)5.2.6. By Company (2019)5.2.7. By Region5.3. Market Attractiveness Index

6. Asia-Pacific Biomaterials Market Outlook6.1. Market Size & Forecast6.1.1. By Value & Volume6.2. Market Share & Forecast6.2.1. By Material Type6.2.2. By Application6.2.3. By Country6.3. Market Attractiveness Index6.4. Asia-Pacific: Country Analysis6.4.1. China Biomaterials Market Outlook6.4.1.1. Market Size & Forecast6.4.1.1.1. By Value6.4.1.2. Market Share & Forecast6.4.1.2.1. By Material Type6.4.1.2.2. By Application6.4.2. India Biomaterials Market Outlook6.4.2.1. Market Size & Forecast6.4.2.1.1. By Value6.4.2.2. Market Share & Forecast6.4.2.2.1. By Material Type6.4.2.2.2. By Application6.4.3. Japan Biomaterials Market Outlook6.4.3.1. Market Size & Forecast6.4.3.1.1. By Value6.4.3.2. Market Share & Forecast6.4.3.2.1. By Material Type6.4.3.2.2. By Application6.4.4. South Korea Biomaterials Market Outlook6.4.4.1. Market Size & Forecast6.4.4.1.1. By Value6.4.4.2. Market Share & Forecast6.4.4.2.1. By Material Type6.4.4.2.2. By Application6.4.5. Singapore Biomaterials Market Outlook6.4.5.1. Market Size & Forecast6.4.5.1.1. By Value6.4.5.2. Market Share & Forecast6.4.5.2.1. By Material Type6.4.5.2.2. By Application6.4.6. Australia Biomaterials Market Outlook6.4.6.1. Market Size & Forecast6.4.6.1.1. By Value6.4.6.2. Market Share & Forecast6.4.6.2.1. By Material Type6.4.6.2.2. By Application

7. Europe Biomaterials Market Outlook7.1. Market Size & Forecast7.1.1. By Value & Volume7.2. Market Share & Forecast7.2.1. By Material Type7.2.2. By Application7.2.3. By Country7.3. Market Attractiveness Index7.4. Europe: Country Analysis7.4.1. France Biomaterials Market Outlook7.4.1.1. Market Size & Forecast7.4.1.1.1. By Value7.4.1.2. Market Share & Forecast7.4.1.2.1. By Material Type7.4.1.2.2. By Application7.4.2. Germany Biomaterials Market Outlook7.4.2.1. Market Size & Forecast7.4.2.1.1. By Value7.4.2.2. Market Share & Forecast7.4.2.2.1. By Material Type7.4.2.2.2. By Application7.4.3. United Kingdom Biomaterials Market Outlook7.4.3.1. Market Size & Forecast7.4.3.1.1. By Value7.4.3.2. Market Share & Forecast7.4.3.2.1. By Material Type7.4.3.2.2. By Application7.4.4. Italy Biomaterials Market Outlook7.4.4.1. Market Size & Forecast7.4.4.1.1. By Value7.4.4.2. Market Share & Forecast7.4.4.2.1. By Material Type7.4.4.2.2. By Application7.4.4.2.3. By End User

8. North America Biomaterials Market Outlook8.1. Market Size & Forecast8.1.1. By Value & Volume8.2. Market Share & Forecast8.2.1. By Material Type8.2.2. By Application8.2.3. By Country8.3. Market Attractiveness Index8.4. North America: Country Analysis8.4.1. United States Biomaterials Market Outlook8.4.1.1. Market Size & Forecast8.4.1.1.1. By Value8.4.1.2. Market Share & Forecast8.4.1.2.1. By Material Type8.4.1.2.2. By Application8.4.2. Mexico Biomaterials Market Outlook8.4.2.1. Market Size & Forecast8.4.2.1.1. By Value8.4.2.2. Market Share & Forecast8.4.2.2.1. By Material Type8.4.2.2.2. By Application8.4.3. Canada Biomaterials Market Outlook8.4.3.1. Market Size & Forecast8.4.3.1.1. By Value8.4.3.2. Market Share & Forecast8.4.3.2.1. By Material Type8.4.3.2.2. By Application

9. South America Biomaterials Market Outlook9.1. Market Size & Forecast9.1.1. By Value & Volume9.2. Market Share & Forecast9.2.1. By Material Type9.2.2. By Application9.2.3. By Country9.3. Market Attractiveness Index9.4. South America: Country Analysis9.4.1. Brazil Biomaterials Market Outlook9.4.1.1. Market Size & Forecast9.4.1.1.1. By Value9.4.1.2. Market Share & Forecast9.4.1.2.1. By Material Type9.4.1.2.2. By Application9.4.2. Argentina Biomaterials Market Outlook9.4.2.1. Market Size & Forecast9.4.2.1.1. By Value9.4.2.2. Market Share & Forecast9.4.2.2.1. By Material Type9.4.2.2.2. By Application9.4.3. Colombia Biomaterials Market Outlook9.4.3.1. Market Size & Forecast9.4.3.1.1. By Value9.4.3.2. Market Share & Forecast9.4.3.2.1. By Material Type9.4.3.2.2. By Application

10. Middle East and Africa Biomaterials Market Outlook10.1. Market Size & Forecast10.1.1. By Value & Volume10.2. Market Share & Forecast10.2.1. By Material Type10.2.2. By Application10.2.3. By Country10.3. Market Attractiveness Index10.4. MEA: Country Analysis10.4.1. South Africa Biomaterials Market Outlook10.4.1.1. Market Size & Forecast10.4.1.1.1. By Value10.4.1.2. Market Share & Forecast10.4.1.2.1. By Material Type10.4.1.2.2. By Application10.4.2. Saudi Arabia Biomaterials Market Outlook10.4.2.1. Market Size & Forecast10.4.2.1.1. By Value10.4.2.2. Market Share & Forecast10.4.2.2.1. By Material Type10.4.2.2.2. By Application10.4.3. UAE Biomaterials Market Outlook10.4.3.1. Market Size & Forecast10.4.3.1.1. By Value10.4.3.2. Market Share & Forecast10.4.3.2.1. By Material Type10.4.3.2.2. By Application

11. Market Dynamics11.1. Drivers11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape13.1. Competition Outlook13.2. Players Profiled (Leading Companies)13.2.1. Koninklijke DSM N.V.13.2.2. Bayer AG13.2.3. Corbion NV13.2.4. Wright Medical Technology, Inc.13.2.5. Zimmer Biomet Holdings, Inc.13.2.6. Collagen Matrix, Inc.13.2.7. Noble Biomaterials Inc13.2.8. Covalon Technologies Ltd13.2.9. Olympus corporation13.2.10. Johnson & Johnson13.2.11. Cook Medical13.2.12. Smith and Nephew13.2.13. Becton Dickinson13.2.14. Medtronic13.2.15. Angiodynamics

14. Strategic Recommendations

15. About Us & Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/j7yiqc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

See more here:
Insights on the Biomaterials Global Market to 2025 - Forecast and Opportunities - PRNewswire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on November 30, 2020.

The presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3 and will also be available on the Investors & Media section of the ElevateBio website at https://www.elevate.bio/investors-and-media. An archived replay of the presentation will be available for approximately 30 days following the presentation.

About ElevateBio

ElevateBio, LLC, is a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies. It begins with an environment where scientific inventors can transform their visions for cell and gene therapies into reality for patients with devastating and life-threatening diseases. Working with leading academic researchers, medical centers, and corporate partners, ElevateBios team of scientists, drug developers, and company builders are creating a portfolio of therapeutics companies that are changing the face of cell and gene therapy and regenerative medicine. Core to ElevateBios vision is BaseCamp, a centralized state-of-the-art innovation and manufacturing center, providing fully integrated capabilities, including basic and transitional research, process development, clinical development, cGMP manufacturing, and regulatory affairs across multiple cell and gene therapy and regenerative medicine technology platforms. ElevateBio portfolio companies, as well as select strategic partners are supported by ElevateBio BaseCamp in the advancement of novel cell and gene therapies.

ElevateBios investors include F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital, The Invus Group, Surveyor Capital (A Citadel company), EDBI, and Vertex Ventures HC.

ElevateBio is headquartered in Cambridge, Mass, with ElevateBio BaseCamp located in Waltham, Mass. For more information, please visit http://www.elevate.bio.

Link:
ElevateBio to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Business Wire

Good lifestyle choices exercising regularly, eating a healthy diet, not smoking, and drinking in moderation obviously makes a big difference in staying healthy. Research in the last few decades has shown, however, that environmental exposures may also contribute to major diseases and health problems that disproportionately affect men, including heart disease, prostate cancer, infertility, and skin cancer.

These exposures involve a number of toxic substances that turn up in food, food packaging, drinking water, and personal care products. Fortunately, there are simple steps men can take to significantly lower their risks.

For example, risk factors for heart disease have been linked to mercury from certain seafoods, Teflon chemicals in non-stick cookware, bisphenol-A (BPA) in hard plastic containers, and canned foods, as well as the arsenic and lead in much of the nations drinking water.

Similarly, prostate cell damage has been traced to the plastics chemical BPA and the heavy metal cadmium. Increased prostate cancer risk has been associated with certain agricultural pesticides common on some fruits and vegetables and polychlorinated biphenyls (PCBs) that build up in meat and dairy products.

And while many people mistakenly think of infertility as primarily a womans problem, the fact is that in about 40% of infertile couples, its the male who is either the sole or a contributing source of the problem. Several studies have tied sperm deficiency to a variety of environmental factors, including exposures to lead, chemicals in personal care products, and pesticides.

Skin cancer is also an especially important issue for men, who are at a higher risk than women of developing and dying from melanoma, the deadliest form.

While many believe that theres not much a man can do about his genetics, this is a common misconception. In fact, many interventions exist that will fix a mans genetic makeup. That is because its not always about what genes you have, but its about what genes are turned on and which ones are turned off.

A huge reason why you will feel better is that you will be turning on good genes and turning off bad genes. This is called epigenetics, which is why you will start feeling so much better. By reversing your current health problems and preventing new ones from starting, you will be empowered to thrive with a healthier lifestyle.

Aside from genetics, there are lots of ways to reduce potentially harmful environmental exposures. Here are five steps you can take immediately:

Invest in the right in-home water filter system to reduce your exposure to lead, arsenic, and other drinking water contaminants.

2. Spot and Avoid Products with BPA

Avoid canned foods and plastic containers with the recycling code No. 7 to lower your exposure to BPA dramatically.

At the supermarket, choose the conventionally grown fruits and vegetables that have the fewest pesticide residues and buy organic versions of those.

4. Know the Grooming Ingredients

When buying deodorant, soap, lotions, and shampoos, consult http://www.EWG.org/skindeep which is an extensive database of nearly 80,000 personal care products to highlight those products that are free of toxic chemicals.

Learn more about skin cancer and melanoma, use proper sun protection, and get regular skin checks with a dermatologist.

Liberally apply sunscreen about 20 to 30 minutes before going outside. And dont forget your ears, scalp, back of neck, and the tops of your feet. Some of the worse burns occur there. Because the sun emits two types of harmful rays UVA and UVB your sunscreen should provide broad-spectrum protection against both.

The specialists at Bingham Healthcare Dermatology highly recommend using sunscreen with an SPF of 30 or greater with the physical UV blockers zinc oxide. (Avoid sunscreens that contain titanium dioxide as studies have shown this could lead to decreased testosterone levels.)

About David J. Bilstrom, MD

Dr. Bilstrom is director of the International Autoimmune Institute & Bingham Memorial Center for Functional Medicine, which is the first medical center in the country to treat all types of autoimmune diseases. It is also the first to use nature, and its ability to improve human health and well-being, as an integral part of a wellness program.

He is quadruple board certified in Functional and Regenerative Medicine, Integrative Medicine, Physical Medicine and Rehabilitation, and Medical Acupuncture. He has extensive experience in Anti-Aging & Regenerative Medicine, Acupuncture, Integrative Medicine, and Complementary and Alternative Medicines.

Dr. Bilstrom works closely with experts in a number of medical specialties to evaluate, diagnose and treat chronic and autoimmune diseases. He is always welcoming new patients at his office within the Bingham Specialty Plaza in Blackfoot. Appointments can be scheduled by calling (208) 782-2444.

Bingham Memorial Specialty Clinic

More:
Toxins, the environment, and your health - Post Register